Cardiopulmonary Exercise Testing Market Trends

Global Cardiopulmonary Exercise Testing Market Overview

Cardiopulmonary Exercise Testing Market size was valued at USD 0.9 billion in 2023. The Cardiopulmonary Exercise Testing Market industry is projected to grow from USD 0.96 billion in 2024 to USD 1.7 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.33% during the forecast period (2024 - 2032).

The factors contributing to the growth of the market are increase in the prevalence of cardiovascular diseases and a rising geriatric population.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In September 2023, Samsung Electronics and the University of Michigan Exercise & Sport Science Initiative (ESSI) initiated a research collaboration to investigate the potential of smartwatch technology in assisting runners with health and physical activity management through the provision of more dependable and precise data. The Michigan Performance Research Laboratory (MiPR), which is the primary research facility of ESSI, will be responsible for conducting an eight-month study that utilizes the Galaxy Watch series to assess the participants' VO2 max and sweat loss when they engage in running activities. 

The study aims to analyze and contrast reference data1 with wristwatch data obtained from both indoor (treadmill) and outdoor running trials of varying distances, ranging from 2.5km to 20km. The Samsung and University of Michigan teams aim to utilize the study's findings to advance smartwatch technology, providing runners with more precise measures of their health parameters to address these concerns. Samsung selected the MiPR lab for this study due to its well-established connections in the wearable tech sector and running community, as well as the exceptional expertise of its experts. The ESSI MiPR lab has partnered with the University of Michigan Athletic Department, various professional sports groups, and industry leaders to extract significant insights from wearable technology that may be utilized in the field of sports and exercise.

In April 2022, Respira Therapeutics, Inc., a clinical-stage company focused on developing inhaled therapeutics for cardiopulmonary diseases, announced that the first patient in the United States has received a dose of its lead product candidate, RT234-PAH. This candidate is a dry powder inhaled treatment containing vardenafil, aimed at improving patient outcomes by targeting the small airways of the lung. The VIPAH-PRN 2b trial will involve two consecutive groups of participants who will receive RT234 as a single dosage through an Axial Oscillating Sphere dry powder inhaler for the treatment of Pulmonary Arterial Hypertension. 

The purpose of this study is to assess the safety and initial effectiveness of RT234 in improving episodic symptoms and exercise capacity in individuals undergoing treatment for pulmonary arterial hypertension (PAH) with New York Heart Association (NYHA) Functional Class II-III symptoms. The commencement of this clinical trial signifies a significant achievement for Respira and is a crucial subsequent action in potentially providing patients with PAH a prompt remedy to alleviate their dyspnea, which hinders their ability to carry out routine tasks.

Cardiopulmonary Exercise Testing Market Trends

•  Growing Prevalence of Cardiovascular Diseases

The growing prevalence of cardiovascular diseases such as heart failure, and pulmonary hypertension among others across the globe is driving the growth of the cardiopulmonary exercise testing market. Cardiopulmonary exercise testing provides valuable diagnostic information and helps in determining exercise capacity and functional limitations in patients with these conditions. According to the article published by National Center for Biotechnology Information in June 2022, the test can provide both cardiac and pulmonary disease processes, while aiding in the development of individualized therapy and rehabilitation programs. Moreover, the increasing prevalence of cardiovascular diseases can be attributed to various factors, including aging populations, sedentary lifestyles, smoking, air pollution, and unhealthy diets. As these diseases progress, they lead to functional limitations, reduced exercise tolerance, and impaired cardiopulmonary fitness. In this context.

The geriatric population is more prone to chronic diseases and adults aged 65 and older are more likely than younger people to suffer from cardiovascular disease. Aging can also cause a risk of developing cardiovascular disease. Thus, the increasing population of this section of people can also increase the demand for cardiopulmonary exercise testing to assess an individual's cardiovascular and respiratory functions. For instance, according to the UN, by 2050, 1 in 6 people around the globe will be over the age of 65, up from 1 in 11 in 2023. According to the Rural Health Information Hub, in the US, the number of older adults aged 65 and older is expected to grow to almost 90 million by 2050. In addition, by 2030, 1 in 5 Americans is projected to be 65 years old or over.

Therefore, the growing prevalence of cardiovascular diseases and other chronic diseases and increasing applications of radioisotopes in the healthcare industry are fueling market growth.

Cardiopulmonary Exercise Testing Market Segment Insights

Cardiopulmonary Exercise Testing Product Type Insights

Based on product type, the Cardiopulmonary Exercise Testing Market has been segmented into CPET metabolic carts and software. The CPET metabolic carts segment dominated the market in 2022, while the software segment is projected to be the fastest-growing during the forecast period, 2023–2030. The segment growth has been driven through factor includes rising prevalence of cardiovascular disease, growing R&D studies, and increasing healthcare expenditure. For instance, COSMED Srl (Italy) launched the 2° generation of OMNIA 2.1 Software, to help clinicians, researchers, and health professionals to provide the highest standard of data management. This is the most comprehensive data management platform for metabolic, lung function and body composition assessment, and cardiopulmonary exercise testing.

Cardiopulmonary Exercise Testing End User Insights

Based on end user, the Cardiopulmonary Exercise Testing Market has been segmented into hospitals & clinics, diagnostic centers, ambulatory centers, and others. The hospitals & clinics segment dominated the market in 2022, while the diagnostic centers segment is projected to be the fastest-growing during the forecast period, 2023–2030. The factors positively contributing to the segment’s growth are increasing preference of individuals, growing healthcare infrastructure, and availability of skilled professionals. The increased number of admissions due to an increase in cardiovascular illnesses is also predicted to drive segment growth throughout the projection period. According to American Heart Association (AHA), each year, more than 356,000 out-of-hospital cardiac arrests (OHCA) occur in the US. Moreover, governments in various emerging countries are also anticipated to boost demand by modernizing healthcare facilities.

Cardiopulmonary Exercise Testing Regional Insights

By region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share of 37.77% in 2022 owing to the presence of active industry players in the region and the availability of the products propelling the market's growth in North America. Additionally, the region’s major growth is positively influenced by increasing incidences of cardiovascular diseases (CVD), which increase the demand for cardiopulmonary exercise testing (CPET) software and CPET metabolic carts. The CPET metabolic carts and software are utilized in CVDs in order to offer an evaluation of the respiratory, cardiovascular, and skeletal muscle systems' integrated exercise responses. According to the American Heart Association, coronary heart disease was one of the leading causes of death in the US in 2020 and account for 41.2% of deaths, followed by stroke (17.3%), other cardiovascular diseases (16.8%), high blood pressure (12.9%), heart failure (9.2%), and artery diseases (2.6%).  Therefore, increasing product launch to meet the demand of physician and patients are fostering the region’s growth.

Further, the major countries studied are: The US, Canada, Brazil, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, Australia.

FIGURE 3: CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The Europe region shows significant growth during the forecast period. This is due to the rising prevalence of chronic diseases such as cardiovascular diseases, respiratory disorders, and metabolic conditions that is driving the demand for CPET in Europe. CPET provides valuable diagnostic and prognostic information for these conditions, aiding in personalized treatment and management strategies. As per the European Survey of Cardiovascular Disease by Daiichi Sankyo Europe GmbH (Germany), there were approximately 60 million people living with CVD, and 13 million new cases were diagnosed in 2020.

Furthermore, according to MedTech Europe, adults aged 65 and older account for more than 80% of coronary artery disease (CAD) cases and more than 75% of congestive heart failure (CHF) cases in Europe. Moreover, the prevalence of CVDs in type 2 (T2) diabetes is as high as 32% in the European population. MedTech Europe reported in September 2022 that approximately 1 out of 3 people—that is, 36% of the European population—accounted for undiagnosed T2, and insulin dependency accounted for 20–30% of the diagnosed T2 population. Furthermore, the France Cardiopulmonary Exercise Testing Market held the largest market share in 2022 and Germany Cardiopulmonary Exercise Testing Market is the fastest growing market in the Europe region.

The growth of the market in Asia-Pacific is predicted to rise rapidly due to an owing to high applications of CPET in the geriatric population as aging populations are more prone to CVDs. As per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022. Furthermore, the chances of having CVDs increase in diabetic patients, which increases the demand for CPET devices. As per the Diabetes Atlas 2021, there were 90 million people diagnosed with diabetes in 2021, expected to reach 113 million by 2030 and 151 million by 2045, which is a flourishing opportunity for the Asia-Pacific market. Moreover, India Cardiopulmonary Exercise Testing Market held the largest market share in 2022 and China Cardiopulmonary Exercise Testing Market is the fastest growing market in the Asia-Pacific region.

Cardiopulmonary Exercise Testing Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product, which will help the Cardiopulmonary Exercise Testing Market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Cardiopulmonary Exercise Testing industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

COSMED srl develops, manufactures, and sells diagnostic medical equipment globally. It offers diagnostic equipment for the metabolism, lungs, and body composition. The company's products include spirometers, Pulmonary Function Test (PFT), Cardiopulmonary Exercise Test (CPET), and indirect calorimetry diagnostic equipment. In addition, COSMED products are designed for either professional or medical use in a variety of settings, including hospitals, clinics, primary care, universities, and education in human physiology, clinical nutrition, commercial weight management, human performance centers, sports institutions, and the health club industry. Moreover, COSMED Srl launched the 2° generation of OMNIA 2.1 Software for clinicians, researchers, and health professionals to provide the highest standard of data management. This is the most comprehensive data management platform for metabolic, lung function and body composition assessment, and cardiopulmonary exercise testing.

Key Companies in the Cardiopulmonary Exercise Testing Market includes.

• Schiller AG


• COSMED srl


• MGC Diagnostics Corporation


• Oxigraf, Inc


• Vyaire Medical, Inc


• CORTEX Biophysik GmbH


• Koninklijke Philips NV


• Hill-Rom Holdings, Inc


• MEDEV Medical Devices Corporation


• Geratherm Medical AG


• COSMED srl


• Others

Cardiopulmonary Exercise Testing Industry Developments

June 2020: MGC Diagnostics (US) signed a distribution agreement with Monitored Therapeutics, Inc. (MTI) (US). In accordance with the terms of the contract, MGC Diagnostics will apply its expertise in diagnostic equipment and cardiopulmonary products to offer in-home solutions and to help medical professionals.

Cardiopulmonary Exercise Testing Market Segmentation

Cardiopulmonary Exercise Testing Product Outlook

• CPET metabolic carts


• software

Cardiopulmonary Exercise Testing End User Outlook

• Hospitals & Clinics


• Diagnostic Centers


• Ambulatory Centers


• Others

Cardiopulmonary Exercise Testing Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • India
  
  
  • Japan
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America